Industry & exhibition
diamond sponsor
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives.
Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.
platinum sponsor
We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy.
Accelerate Innovative Science: Accelerating the next wave of new molecular entities, building our capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity Deliver Growth and Therapy Area Leadership: Meeting our growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition Be a Great Place to Work: Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering our Ambition Zero Carbon program.
Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society. We are committed to operating in a way that recognizes the interconnection between business growth, the needs of society and the limitations of our planet.
gold sponsor
GSK is a science-led global healthcare company on a mission to research, develop, manufacture and market innovative medicines and vaccines to unite science, technology and talent to get ahead of disease together.
GSK has a 300-year global legacy, and for more than 65 years has been operating, employing and investing in the Gulf Cooperation Council region. We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
We are a company where outstanding people can thrive.
We are a global, research-driven company, powered and inspired by the diversity of our people - hailing from over 170 countries, countless cultures and backgrounds.
We believe in the collective power of all these individuals in the tireless pursuit of science and solutions that are accessible to ever more people and their animals. Because of them, we bring hope, opportunity, relief and joy to millions all over the globe.
Together, we are building a healthier, more sustainable, and equitable tomorrow.
Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the Middle East / North Africa (MENA) region. Positioned across 17+ key strategic locations in the Gulf Cooperation Council (GCC), Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for difficult-to-treat diseases.
A privately owned pharmaceutical company organized under the laws of the United Arab Emirates (UAE), Biologix provides end-to-end solutions from the preregistration phase all the way to commercial-scale market access and risk management. Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997.
We were among the first organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches.
SILVER sponsor
Chiesi is an international group based in Parma, research-oriented, with over 85 years of experience, present in 30 countries. The Chiesi Group researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from infants to adults), RARE (innovative solutions and personalized services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care, personal care and well-being).
Since 2019 Chiesi has been the largest pharmaceutical group in the world certified B Corp, while, in 2018, Chiesi changed its legal status to a Benefit Company, realizing the desire to measure its impact on society and the environment, combining the need to generate value for the business to acting as a positive force for the community in which we live.
Chiesi is among the top 50 pharmaceutical companies in the world. The Group's Research and Development is based in Parma and integrates with six other major research centers in France, the United States, Canada, China, the United Kingdom and Sweden, to promote its preclinical, clinical and regulatory programs. Its production activity, on the other hand, takes place in three plants located in Parma (Italy), Blois (France) and Santana de Parnaiba (Brazil).